Click for best price
Cardiometabolic Diseases Market Size, Share 2024
Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.
This report aims to provide a comprehensive presentation of the global market for Cardiometabolic Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiometabolic Diseases. This report contains market size and forecasts of Cardiometabolic Diseases in global, including the following market information:
Global Cardiometabolic Diseases Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
The global Cardiometabolic Diseases market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
ACE Inhibitors Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Cardiometabolic Diseases include Eli Lilly and Company, Bayer AG, Arrowhead Pharmaceuticals, Inc, Novartis AG, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc. and Cardax, Inc, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cardiometabolic Diseases companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cardiometabolic Diseases Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Cardiometabolic Diseases Market Segment Percentages, by Type, 2023 (%)
ACE Inhibitors
Diuretics
Glucophage
Others
Global Cardiometabolic Diseases Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Cardiometabolic Diseases Market Segment Percentages, by Application, 2023 (%)
Hospitals
Clinics
Others
Global Cardiometabolic Diseases Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Cardiometabolic Diseases Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cardiometabolic Diseases revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Cardiometabolic Diseases revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly and Company
Bayer AG
Arrowhead Pharmaceuticals, Inc
Novartis AG
Boehringer Ingelheim International GmbH
Novo Nordisk A/S
AstraZeneca
Alnylam Pharmaceuticals, Inc.
Cardax, Inc
Kowa Company, Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cardiometabolic Diseases, market overview.
Chapter 2: Global Cardiometabolic Diseases market size in revenue.
Chapter 3: Detailed analysis of Cardiometabolic Diseases company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cardiometabolic Diseases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Cardiometabolic Diseases Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
62 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Cardiometabolic Diseases Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cardiometabolic Diseases Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cardiometabolic Diseases Overall Market Size
2.1 Global Cardiometabolic Diseases Market Size: 2023 VS 2030
2.2 Global Cardiometabolic Diseases Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Cardiometabolic Diseases Players in Global Market
3.2 Top Global Cardiometabolic Diseases Companies Ranked by Revenue
3.3 Global Cardiometabolic Diseases Revenue by Companies
3.4 Top 3 and Top 5 Cardiometabolic Diseases Companies in Global Market, by Revenue in 2023
3.5 Global Companies Cardiometabolic Diseases Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cardiometabolic Diseases Players in Global Market
3.6.1 List of Global Tier 1 Cardiometabolic Diseases Companies
3.6.2 List of Global Tier 2 and Tier 3 Cardiometabolic Diseases Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Cardiometabolic Diseases Market Size Markets, 2023 & 2030
4.1.2 ACE Inhibitors
4.1.3 Diuretics
4.1.4 Glucophage
4.1.5 Others
4.2 By Type - Global Cardiometabolic Diseases Revenue & Forecasts
4.2.1 By Type - Global Cardiometabolic Diseases Revenue, 2019-2024
4.2.2 By Type - Global Cardiometabolic Diseases Revenue, 2025-2030
4.2.3 By Type - Global Cardiometabolic Diseases Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Cardiometabolic Diseases Market Size, 2023 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Cardiometabolic Diseases Revenue & Forecasts
5.2.1 By Application - Global Cardiometabolic Diseases Revenue, 2019-2024
5.2.2 By Application - Global Cardiometabolic Diseases Revenue, 2025-2030
5.2.3 By Application - Global Cardiometabolic Diseases Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Cardiometabolic Diseases Market Size, 2023 & 2030
6.2 By Region - Global Cardiometabolic Diseases Revenue & Forecasts
6.2.1 By Region - Global Cardiometabolic Diseases Revenue, 2019-2024
6.2.2 By Region - Global Cardiometabolic Diseases Revenue, 2025-2030
6.2.3 By Region - Global Cardiometabolic Diseases Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Cardiometabolic Diseases Revenue, 2019-2030
6.3.2 US Cardiometabolic Diseases Market Size, 2019-2030
6.3.3 Canada Cardiometabolic Diseases Market Size, 2019-2030
6.3.4 Mexico Cardiometabolic Diseases Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Cardiometabolic Diseases Revenue, 2019-2030
6.4.2 Germany Cardiometabolic Diseases Market Size, 2019-2030
6.4.3 France Cardiometabolic Diseases Market Size, 2019-2030
6.4.4 U.K. Cardiometabolic Diseases Market Size, 2019-2030
6.4.5 Italy Cardiometabolic Diseases Market Size, 2019-2030
6.4.6 Russia Cardiometabolic Diseases Market Size, 2019-2030
6.4.7 Nordic Countries Cardiometabolic Diseases Market Size, 2019-2030
6.4.8 Benelux Cardiometabolic Diseases Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Cardiometabolic Diseases Revenue, 2019-2030
6.5.2 China Cardiometabolic Diseases Market Size, 2019-2030
6.5.3 Japan Cardiometabolic Diseases Market Size, 2019-2030
6.5.4 South Korea Cardiometabolic Diseases Market Size, 2019-2030
6.5.5 Southeast Asia Cardiometabolic Diseases Market Size, 2019-2030
6.5.6 India Cardiometabolic Diseases Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Cardiometabolic Diseases Revenue, 2019-2030
6.6.2 Brazil Cardiometabolic Diseases Market Size, 2019-2030
6.6.3 Argentina Cardiometabolic Diseases Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Cardiometabolic Diseases Revenue, 2019-2030
6.7.2 Turkey Cardiometabolic Diseases Market Size, 2019-2030
6.7.3 Israel Cardiometabolic Diseases Market Size, 2019-2030
6.7.4 Saudi Arabia Cardiometabolic Diseases Market Size, 2019-2030
6.7.5 UAE Cardiometabolic Diseases Market Size, 2019-2030
7 Cardiometabolic Diseases Companies Profiles
7.1 Eli Lilly and Company
7.1.1 Eli Lilly and Company Company Summary
7.1.2 Eli Lilly and Company Business Overview
7.1.3 Eli Lilly and Company Cardiometabolic Diseases Major Product Offerings
7.1.4 Eli Lilly and Company Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.1.5 Eli Lilly and Company Key News & Latest Developments
7.2 Bayer AG
7.2.1 Bayer AG Company Summary
7.2.2 Bayer AG Business Overview
7.2.3 Bayer AG Cardiometabolic Diseases Major Product Offerings
7.2.4 Bayer AG Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.2.5 Bayer AG Key News & Latest Developments
7.3 Arrowhead Pharmaceuticals, Inc
7.3.1 Arrowhead Pharmaceuticals, Inc Company Summary
7.3.2 Arrowhead Pharmaceuticals, Inc Business Overview
7.3.3 Arrowhead Pharmaceuticals, Inc Cardiometabolic Diseases Major Product Offerings
7.3.4 Arrowhead Pharmaceuticals, Inc Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.3.5 Arrowhead Pharmaceuticals, Inc Key News & Latest Developments
7.4 Novartis AG
7.4.1 Novartis AG Company Summary
7.4.2 Novartis AG Business Overview
7.4.3 Novartis AG Cardiometabolic Diseases Major Product Offerings
7.4.4 Novartis AG Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.4.5 Novartis AG Key News & Latest Developments
7.5 Boehringer Ingelheim International GmbH
7.5.1 Boehringer Ingelheim International GmbH Company Summary
7.5.2 Boehringer Ingelheim International GmbH Business Overview
7.5.3 Boehringer Ingelheim International GmbH Cardiometabolic Diseases Major Product Offerings
7.5.4 Boehringer Ingelheim International GmbH Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.5.5 Boehringer Ingelheim International GmbH Key News & Latest Developments
7.6 Novo Nordisk A/S
7.6.1 Novo Nordisk A/S Company Summary
7.6.2 Novo Nordisk A/S Business Overview
7.6.3 Novo Nordisk A/S Cardiometabolic Diseases Major Product Offerings
7.6.4 Novo Nordisk A/S Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.6.5 Novo Nordisk A/S Key News & Latest Developments
7.7 AstraZeneca
7.7.1 AstraZeneca Company Summary
7.7.2 AstraZeneca Business Overview
7.7.3 AstraZeneca Cardiometabolic Diseases Major Product Offerings
7.7.4 AstraZeneca Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.7.5 AstraZeneca Key News & Latest Developments
7.8 Alnylam Pharmaceuticals, Inc.
7.8.1 Alnylam Pharmaceuticals, Inc. Company Summary
7.8.2 Alnylam Pharmaceuticals, Inc. Business Overview
7.8.3 Alnylam Pharmaceuticals, Inc. Cardiometabolic Diseases Major Product Offerings
7.8.4 Alnylam Pharmaceuticals, Inc. Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.8.5 Alnylam Pharmaceuticals, Inc. Key News & Latest Developments
7.9 Cardax, Inc
7.9.1 Cardax, Inc Company Summary
7.9.2 Cardax, Inc Business Overview
7.9.3 Cardax, Inc Cardiometabolic Diseases Major Product Offerings
7.9.4 Cardax, Inc Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.9.5 Cardax, Inc Key News & Latest Developments
7.10 Kowa Company, Ltd.
7.10.1 Kowa Company, Ltd. Company Summary
7.10.2 Kowa Company, Ltd. Business Overview
7.10.3 Kowa Company, Ltd. Cardiometabolic Diseases Major Product Offerings
7.10.4 Kowa Company, Ltd. Cardiometabolic Diseases Revenue in Global Market (2019-2024)
7.10.5 Kowa Company, Ltd. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Cardiometabolic Diseases Market Opportunities & Trends in Global Market
Table 2. Cardiometabolic Diseases Market Drivers in Global Market
Table 3. Cardiometabolic Diseases Market Restraints in Global Market
Table 4. Key Players of Cardiometabolic Diseases in Global Market
Table 5. Top Cardiometabolic Diseases Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Cardiometabolic Diseases Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Cardiometabolic Diseases Revenue Share by Companies, 2019-2024
Table 8. Global Companies Cardiometabolic Diseases Product Type
Table 9. List of Global Tier 1 Cardiometabolic Diseases Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cardiometabolic Diseases Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Cardiometabolic Diseases Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Cardiometabolic Diseases Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Cardiometabolic Diseases Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Cardiometabolic Diseases Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Cardiometabolic Diseases Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Cardiometabolic Diseases Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Cardiometabolic Diseases Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Cardiometabolic Diseases Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Cardiometabolic Diseases Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Cardiometabolic Diseases Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Cardiometabolic Diseases Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Cardiometabolic Diseases Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Cardiometabolic Diseases Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Cardiometabolic Diseases Revenue, (US$, Mn), 2025-2030
Table 30. Eli Lilly and Company Company Summary
Table 31. Eli Lilly and Company Cardiometabolic Diseases Product Offerings
Table 32. Eli Lilly and Company Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 33. Eli Lilly and Company Key News & Latest Developments
Table 34. Bayer AG Company Summary
Table 35. Bayer AG Cardiometabolic Diseases Product Offerings
Table 36. Bayer AG Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 37. Bayer AG Key News & Latest Developments
Table 38. Arrowhead Pharmaceuticals, Inc Company Summary
Table 39. Arrowhead Pharmaceuticals, Inc Cardiometabolic Diseases Product Offerings
Table 40. Arrowhead Pharmaceuticals, Inc Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 41. Arrowhead Pharmaceuticals, Inc Key News & Latest Developments
Table 42. Novartis AG Company Summary
Table 43. Novartis AG Cardiometabolic Diseases Product Offerings
Table 44. Novartis AG Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 45. Novartis AG Key News & Latest Developments
Table 46. Boehringer Ingelheim International GmbH Company Summary
Table 47. Boehringer Ingelheim International GmbH Cardiometabolic Diseases Product Offerings
Table 48. Boehringer Ingelheim International GmbH Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 49. Boehringer Ingelheim International GmbH Key News & Latest Developments
Table 50. Novo Nordisk A/S Company Summary
Table 51. Novo Nordisk A/S Cardiometabolic Diseases Product Offerings
Table 52. Novo Nordisk A/S Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 53. Novo Nordisk A/S Key News & Latest Developments
Table 54. AstraZeneca Company Summary
Table 55. AstraZeneca Cardiometabolic Diseases Product Offerings
Table 56. AstraZeneca Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 57. AstraZeneca Key News & Latest Developments
Table 58. Alnylam Pharmaceuticals, Inc. Company Summary
Table 59. Alnylam Pharmaceuticals, Inc. Cardiometabolic Diseases Product Offerings
Table 60. Alnylam Pharmaceuticals, Inc. Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 61. Alnylam Pharmaceuticals, Inc. Key News & Latest Developments
Table 62. Cardax, Inc Company Summary
Table 63. Cardax, Inc Cardiometabolic Diseases Product Offerings
Table 64. Cardax, Inc Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 65. Cardax, Inc Key News & Latest Developments
Table 66. Kowa Company, Ltd. Company Summary
Table 67. Kowa Company, Ltd. Cardiometabolic Diseases Product Offerings
Table 68. Kowa Company, Ltd. Cardiometabolic Diseases Revenue (US$, Mn) & (2019-2024)
Table 69. Kowa Company, Ltd. Key News & Latest Developments
List of Figures
Figure 1. Cardiometabolic Diseases Segment by Type in 2023
Figure 2. Cardiometabolic Diseases Segment by Application in 2023
Figure 3. Global Cardiometabolic Diseases Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Cardiometabolic Diseases Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Cardiometabolic Diseases Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cardiometabolic Diseases Revenue in 2023
Figure 8. By Type - Global Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 9. By Application - Global Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 10. By Type - Global Cardiometabolic Diseases Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 12. By Application - Global Cardiometabolic Diseases Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 14. By Region - Global Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 15. By Country - North America Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 16. US Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 20. Germany Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 21. France Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 28. China Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 32. India Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 34. Brazil Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Cardiometabolic Diseases Revenue Market Share, 2019-2030
Figure 37. Turkey Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Cardiometabolic Diseases Revenue, (US$, Mn), 2019-2030
Figure 41. Eli Lilly and Company Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Bayer AG Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Arrowhead Pharmaceuticals, Inc Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Novartis AG Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Boehringer Ingelheim International GmbH Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Novo Nordisk A/S Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. AstraZeneca Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Alnylam Pharmaceuticals, Inc. Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Cardax, Inc Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Kowa Company, Ltd. Cardiometabolic Diseases Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
